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ajor histocompatibility complex class I downregu-Ag presentation machinery, including TAP-, tapasin-, and lation represents a 
signiﬁcant challenge for suc-proteasome-deﬁcient cancer cells (4–10). Our studies also cessful T cell–based cancer immunotherapy. 
Indeed, revealed the existence of a broad unique TEIPP-speciﬁc T cell immunotherapy studies in melanoma patients have previously 
repertoire that is highly speciﬁc to only Ag presentation mademonstrated that progression of cancer lesions is linked to chinery–deﬁcient 
cancer cells (5, 8, 10). These TEIPP-speciﬁc reduced MHC class I (MHC-I)/peptide cell surface expression, T cells are selected in the 
thymus, egress with a naive phenowhereas cancer lesions with normal expression regressed in the type, and can be efﬁciently exploited 
for immunotherapy same patient (1–3). We have previously demonstrated the ex-against immune-escaped, TAP-deﬁcient tumor cells 
expressing istence of a new class of hidden MHC-I–presented self-peptides, low levels of MHC-I/peptide complexes (5). However, 
priming termed T cell epitope associated with impaired peptide pro-of these TEIPP-speciﬁc T cells is required through exposition to 
cessing (TEIPP), that only appear in tumor cells with defective APCs with normal MHC-I expression (11).  
We have also recently determined the crystal structure of H-2D
b 
in complex with the ﬁrst prototypic TEIPP peptide Trh4 (12). The 
structure revealed that the peptide takes a noncanonical peptidebinding pattern forming extensive sulfur–p interactions that contribute to 
the overall complex stability. Indeed, in contrast to all previously reported crystal structures of H-2D
b 
epitopes, the TEIPP peptide Trh4 
(MCLRMTAVM), derived from the commonly expressed cellular protein Trh4 (10, 13), does not contain an asparagine at position 5 and 
comprises an unusually large number of sulfur-containing residues at positions 1, 2, 5, and 9. The crystal structure of H-2D
b
/Trh4 
combined with site-directed mutagenesis analysis on peptide binding capacity revealed that Trh4 makes primary use of peptide residues 
p2C, p5M, and p9M for binding, interacting with speciﬁc aromatic residues in H-2D
b 
(12). Indeed, the removal of sulfur atoms through 
the conservative substitutions of p2C or p5M to a-aminobutyric acid and norleucine, respectively, severely reduced the overall stability 
of the H-2D
b 
complexes, indicating the importance of SH–p and van der Waals interactions for the stability of the MHC/peptide 
complex. 
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Human cancers frequently display defects in Ag processing and presentation allowing for immune evasion, and they therefore constitute 
a signiﬁcant challenge for T cell–based immunotherapy. We have previously demonstrated that the antigenicity of tumor-associated Ags 
can be signiﬁcantly enhanced through unconventional residue modiﬁcations as a novel tool for MHC class I (MHC-I)–based 
immunotherapy approaches. We have also previously identiﬁed a novel category of cancer neo-epitopes, that is,T cell epitopes associated 
with impaired peptide processing (TEIPP), that are selectively presented by MHC-I on cells lacking the peptide transporterTAP.In this 
study, we demonstrate that substitutionof the nonanchoring position3intoa proline residue oftheﬁrst identiﬁed TEIPP peptide,the 
murineTrh4, resultsin signiﬁcantly enhanced recognitionby antitumorCTLs towardthe wild-type epitope. Although higher 
immunogenicity has in most cases been associated with increased MHC/peptide complex stability, our results demonstrate that the 
overall stability of H-2D
b 
in complex with the highly immunogenic altered peptide ligandTrh4-p3Pis signiﬁcantlyreduced compared with 
wild-typeH-2D
b
/Trh4.ComparisonofthecrystalstructuresoftheH-2D
b
/Trh4-p3P and H-2D
b
/Trh4 complexes revealed that the conformation 
of the nonconventional methionine anchor residue p5M is altered, deleting its capacity to form adequate sulfur–p interactions with H-2D
b 
residues, thus reducing the overall longevity of the complex. Collectively, our results indicate that vaccination with Thr4-p3P 
signiﬁcantly enhances T cell recognition of targets presenting the wild-type TEIPP epitope and that higher immunogenicity is not 
necessarily directly related to MHC/peptide complex stability, opening for the possibility to design novel peptide vaccines with reduced 
MHC/peptide complex stability.  
 
An additional important result from this previous study was that 
the methionine at peptide position 5 (p5M) in Trh4 signiﬁcantly 
alters the conformation of the H-2D
b 
residues Y156 and H155, 
both important for T cell recognition, resulting in the formation of 
a unique MHC/peptide conformer that is essential for recognition 
by TEIPP-speciﬁc T cells (12, 14). Indeed, substitution of the 
main anchor position p5M in Trh4 to a conventional asparagine, 
as found in most H-2D
b–
binding peptides, signiﬁcantly reduced the 
overall stability of the MHC/peptide complex and abolished rec-
ognition by the H-2D
b
/Trh4–speciﬁc T cell LnB5, indicating the 
importance of the subtle interplay between p5M and H155 for 
adequate T cell recognition (12).  
In vaccination studies with the TEIPP Ag Trh4 we established 
that cognate TCR-transgenic T cells poorly respond to the wild-
type Trh4 peptide, even though it forms a stable complex with 
H-2D
b 
(12). Others and we previously demonstrated that 
alteration of cancer-associated epitopes at the nonanchoring 
peptide position 3 to a proline residue in H-2D
b
–binding epitopes 
strongly increases the MHC/peptide complex stability and 
immunogenicity (15–17). The introduced proline residue forms 
CH–p and van der Waals interactions with the H-2D
b 
residue 
Y159 (Supplemental Fig. 1), highly conserved among most 
known MHC-I alleles. For example, the p3P modiﬁcation 
signiﬁcantly increased the afﬁnity of the 
H-2D
b
/gp10025–33-speciﬁc TCR pMel. Peptide vaccination using 
the mimotope gp10025–33-p3P induced high frequencies of 
melanoma-speciﬁc CTLs in the endogenous CD8
+ 
repertoire and 
resulted in dramatically enhanced in vivo responses toward mel-
anoma tumors (15). Surprisingly, the enhanced TCR binding was 
independent from the observed increased stability of the 
optimized H-2D
b
/gp10025–33 complex and from the interactions 
formed between p3P and Y159, as demonstrated by progressive 
mutation of Y159 to phenylalanine, leucine, and alanine, 
indicating a direct effect of the p3P modiﬁcation on TCR 
recognition, most probably through proline-induced rigidiﬁcation 
of the presented peptide (18).  
In this study, we intended to expand our previous results based on 
the p3P modiﬁcation obtained on conventional tumor-associated 
Ags onto the TEIPP peptide Trh4. We have investigated the 
characteristics of the p3P modiﬁcation on the Trh4 epitope and 
the in vitro and in vivo CTL responses using the TCR-transgenic 
LnB5 mouse model. Our results demonstrate that vaccination 
with Trh4p3P induced extremely robust Trh4-speciﬁc CTL 
responses with high frequencies and effector functions, including 
IFN-g release, downregulation of CD62L, and in vivo killing 
capacity. Interestingly, and in contrast to the previously studied 
tumor-associated Ags, although much more immunogenic, the 
H-2D
b
/Trh4-p3P complex was clearly less stable on the cell 
surface as well as in solution compared with the wild-type 
H-2D
b
/Thr4 complex. Thus, our results stand in contrast to the 
present notion that higher immunogenicity is directly linked to 
higher MHC/peptide complex stability (19), and they indicate that 
rigidiﬁcation of the altered peptide ligand combined with absolute 
molecular mimicry compared with the wild-type neoantigen are 
key for enhanced TCR recognition. Collectively, our results 
extend our earlier ﬁndings on p3P-exchanged peptide epitopes to 
TEIPP-directed CTL responses for recognition of cancer cells 
with low MHC/peptide expression levels. They also demonstrate 
that this alternative approach may be used within the frame of 
vaccination strategies to counteract viruses and cancers.  
 
Materials and Methods  
Cell lines and mice  
The tumor cell lines RMA and RMA-S (TAP-2 deﬁcient) have been pre-
viously described (6, 10). The CD8
+ 
T cell clone LnB5, speciﬁc for H-2D
b
/ 
Trh4, was generated and cultured as described previously (5, 6). All cells 
were cultured in complete IMDM medium containing 8% heat-inactivated 
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine 
(Invitrogen) at 37˚C in humidiﬁed air with 5% CO2. C57BL/6 mice were 
purchased from Charles River Laboratories. The generation of LnB5-
transgenic (tg) mice has been recently described in detail (5). All experi-
ments with mice were approved by the local Inspection for Animal 
Welfare under the institutional permit from the Dutch government with 
number AVD116002015271.  
T cell recognition assays  
The LnB5 T cell clone (3 3 10
3
) was mixed overnight in 100 mlofculture 
medium in the presence of Trh4 peptide variants and splenocytes (50 3 
10
3
). The following day, levels of IFN-g in the supernatants were assessed 
by sandwich ELISA, as described before (6, 12). The presented data 
represent mean values obtained from triplicate test wells, and error bars 
represent the SD of these values.  
Adoptive T cell transfer and peptide vaccination  
Single-cell suspensions of LnB5-tg T cells were made by mechanical dis-
ruption of spleen and lymph nodes from LnB5-tg C57BL/6 mice (5). Cells 
were passed through nylon wool for enrichment of T cells, and 3 3 10
6 
CD8
+ 
T cells in PBS were injected i.v. in syngeneic recipient C57BL/6 
mice. The next day, mice were vaccinated s.c. with 50 mg of the 9-mer 
wild-type Trh4 (MCLRMTAVM) or the p3P peptide variant 
(MCPRMTAVM) in 100 mlof PBS. The vaccination site was overlaid 
directly after vaccination with 60 mg of the adjuvant 
imiquimod-containing cream Aldara (Meda). Peptide vaccination was 
repeated at day 8 and recombinant human IL-2 (600,000 IU) was injected 
i.p. at days 8 and 9. T cell activation was measured in blood taken from the 
tail vein of the mice. To assess IFN-g production by LnB5-tg cells, blood 
of recipient mice was cultured overnight in the presence of 1 mg/ml 
wild-type Trh4 peptide. The next day, intracellular cytokine staining was 
performed as described before (5). Abs used were speciﬁc for CD8 (clone 
53-6.7), CD45.1 (A20), CD62L (MEL-14) and IFN-g (XMG1.2) 
(eBioscience). Data were acquired on an LSRFortessa or FACSCalibur 
(BD Biosciences, San Diego, CA). Analysis was performed with FlowJo 
software (Tree Star).  
The in vivo cytotoxicity assays were performed as previously described 
(5). In short, C57BL/6 mice were injected with LnB5-tg cells and vacci-
nated with Trh4 or Trh4-p3P peptide twice. One week after the second 
vaccination, mice were challenged with CFSE-loaded splenocytes pulsed 
with either the wild-type Trh4 peptide or the H-2D
b
–binding control 
peptide Ad10 (SGPSNTPPEI). Two days after challenge, spleens were 
harvested and the percentage of speciﬁc killing was assessed by ﬂow 
cytometry.  
Peptide/MHC cell-surface afﬁnity assays  
Peptide binding afﬁnities were determined using cell surface expression 
levels of H-2D
b 
on peptide-pulsed TAP-deﬁcient RMA-S cells (15). In 
short, RMA-S cells were pulsed with the HIV-derived H-2D
d
–binding 
epitope P18-I10 (RGPGRAFVTI) (20, 21) and the lymphocytic chorio-
meningitis virus–derived immunodominant H-2D
b
–binding peptide gp33 
(KAVYNFATM) (22), which were used as negative and positive controls, 
respectively, together with the wild-type Trh4 and the Trh4-p3P altered 
peptide ligand variant at the indicated concentration at 26˚C overnight 
(Fig. 1A). Cell surface expression levels of H-2D
b
/peptide complexes 
were assessed on RMA-S cells using the monoclonal anti–H-2D
b 
Ab 
KH95 (BD Biosciences). 
The mean ﬂuorescence intensity (MFI) measured and the peptide binding 
afﬁnity were calculated using the formula: [(MFI (peptide) 2 MFI (no 
peptide)]/MFI (no peptide).  
Peptide/MHC cell surface stabilization assays  
RMA-S cells were cultured with 10
26 
M of each peptide for 12 h at 26˚C in 
5% CO2. Cells were thereafter incubated at 37˚C for 1 h, then washed in 
cold serum-and peptide-free medium, and resuspended in prewarmed 
(37˚C) peptide-and serum-free AIM-V medium (Invitrogen) containing 5 
mg/ml brefeldin A (Sigma-Aldrich). Cells collected at time points 1, 2, 4, 
and 6 h were stained with anti–H-2D
b 
Ab (clone 28-14-8), washed with 
PBS, and ﬁxed using 1% paraformaldehyde. Cell surface expression of 
H-2D
b 
was determined using a BD FACSCalibur (BD Biosciences). The 
MFI was calculated as indicated above and cell surface H-2D
b 
expression 
at time point 1 h for each peptide was deﬁned as 100% MHC/peptide. 
Data were analyzed using FlowJo software (Tree Star).  
Thermostability measurements using circular dichroism  
Circular dichroism measurements were performed in 20 mM K2HPO4/ 
KH2PO4 (pH 7.5) using protein concentrations between 0.15 and 0.25 
mg/ml (23). Spectra were recorded with a JASCO J-810 
spectropolarimeter (JASCO Analytical Instruments, Great Dunmow, 
U.K.) equipped with a thermoelectric temperature controller in a 2-mm 
cell. MHC/peptide complex denaturation was measured between 20 and 
65˚C at 218 nm with a gradient of 48˚C/h at 0.1˚C increments and an 
averaging time of 8 s. The melting curves were scaled from 0 to 100%, 
and the melting temperature (Tm) values were extracted using a sigmoidal 
ﬁt to the individual sample data and averaging the deﬂection points for 
each complex. Curves and Tm values are an average of at least two 
measurements from at least two independent refolding assays per 
complex. Spectra were analyzed and ﬁgures created using GraphPad 
Prism 7 (GraphPad Software). Statistics were analyzed using a Student t 
test.  
Preparation and crystallization of the H-2D
b
/Trh4-p3P MHC-I 
complex  
The altered peptide variant Trh4-p3P in which position 3 was substituted 
to a proline (MCPRMTAVM) was prepared by microwave-assisted 
solid-phase synthesis based on F-moc chemistry (24) on a CEM Liberty 
peptide synthesizer. The peptide was puriﬁed by reversed phase HPLC on 
a Jasco BS997-01 instrument equipped with a Denali C-18 column from 
Grace Vydac (10 mm, 250 3 22 mm). Refolding and puriﬁcation of the 
H-2D
b
/Trh4-p3P complex was performed according to previously 
published protocols (20, 22, 25, 26). Crystals for the H-2D
b
/Trh4-p3P 
complex were obtained by using the hanging drop vapor diffusion 
method. The best crystals appeared in 2 M ammonium sulfate, 0.1 M 
Tris-HCl (pH 8), and 0.5 M NaCl at 4˚C. Two microliters of 3 mg/ml 
protein solution in 20 mM Tris-HCl (pH 7.5) and 150 mM NaCl was 
mixed with 1 ml of crystallization reservoir solution, and thereafter 
equilibrated against 1 ml of well solution at 4˚C.  
Data collection and processing  
Data collection for the H-2D
b
/Trh4-p3P complex was performed 
under cryogenic conditions (temperature 100 K) at beam line 14.1 (Bessy, 
Berlin, Germany) to 2.4 A resolution. Crystals were soaked in a 
cryoprotectant ˚solution containing 20% glycerol before freezing. A total 
of 600 images were collected, with 0.3˚ oscillation per frame. Data were 
processed with MOSFLM (27) and AIMLESS (28) from the CCP4 suite. 
The H-2D
b
/Trh4p3P complex crystals belong to the I2 space group. Data 
collection statistics are provided in Supplemental Table I.  
 
Crystal structure determination and reﬁnement  
The crystal structure of the H-2D
b
/Trh4-p3P complex was determined by 
molecular replacement using Phaser (29) and the H-2D
b
/gp33 complex with 
the peptide omitted (Protein Data Bank code 1S7U) (22, 30) as a search 
model. The program Phaser found the solution with two molecules in the 
asymmetric unit. Five percent of the total amount of reﬂections was set 
aside for monitoring reﬁnement by Rfree. Reﬁnement of the crystal 
structure was performed using REFMAC (31) and Phenix (32). A clearly 
interpretable electron density was observed in the peptide-binding cleft, 
and the Thr4-p3P peptide could be unambiguously modeled in all MHC 
complexes within the asymmetric unit. Water molecules were added using 
COOT (33) and their position was inspected manually. The stereochem-
istry of the ﬁnal model of the H-2D
b
/Trh4-p3P complex was veriﬁed with  
COOT. The ﬁnal reﬁnement parameters are presented in Supplemental 
Table I. Figures were created using the program PyMOL (PyMOL Mo 
lecular Graphics System, version 1.8; Schro¨dinger).  
Statistical analysis  
Statistical analysis was performed using GraphPad Prism 6. A p value ,  
0.05 was considered statistically signiﬁcant.  
Results  
The proline-modiﬁed Trh4-p3P peptide induces robust CTL 
responses  
We initiated the present study by assessing CTL responses upon 
peptide vaccination in C57BL/6 mice that received a low number 
(3 3 10
6
)of CD8
+ 
T cells carrying a tg TCR recognizing the 
H-2D
b 
/Trh4, named LnB5 (5). Peptide vaccination was 
performed with synthetic short peptides of Trh4 or the 
adenovirus-derived control Ag Ad10 together with imiquimod 
adjuvant. A booster vaccination was provided after 1 wk. 
Although increased frequencies of transgenic LnB5 T cells were 
detectable after peptide vaccination with Trh4 compared with 
control peptide (8% versus 2%, respectively, on day 12), the 
amplitude of the response was weak (Fig. 1A). We then 
investigated whether the previously described p3P modiﬁcation  
(15) of the Trh4 peptide would induce enhanced CTL responses 
by determining T cell recognition of this peptide in vitro using the 
LnB5-tg CTLs. The Trh4-p3P peptide induced much stronger 
CTL activation even at lower peptide concentrations compared 
with the wild-type Trh4 peptide. Indeed, IC50 values were ∼
10-fold increased (Fig. 1B). Next, the effects of the Trh4-p3P 
peptide were examined in our mouse model with transferred 
TCR-tg T cells, and our results demonstrate an extremely robust 
CTL response (Fig. 1C–F). At the peak of the response, 5 d after 
the booster vaccination, up to 80% of all CD8
+ 
T cells in the blood 
were tg LnB5 T cells, indicating a remarkable clonal expansion. 
In contrast, vaccination with the wild-type Trh4 peptide resulted 
in ,8% LnB5 T cells (Fig. 1C). Furthermore, LnB5-tg T cells 
activated by the Trh4-p3P peptide displayed robust effector 
functions, as indicated by signiﬁcantly higher levels of 
IFN-g–producing T cells (Fig. 1D), efﬁcient loss of the lymph 
node homing receptor CD62L (Fig. 1E), and strong in vivo killing 
of peptide-loaded targets (Fig. 1F). In conclusion, vaccination 
with Trh4-p3P resulted in signiﬁcant in vivo proliferation and 
enhanced effector functions of TEIPP-speciﬁc T cells, in contrast 
to vaccination with the wild-type Trh4 neoepitope. These 
improvements at the T cell level were even more impressive than 
those previously observed with the melanomaassociated Ag 
gp100 (15).  
Proline substitution signiﬁcantly alters the binding kinetics of 
Trh4-p3P  
We have previously demonstrated that substitution of the third 
position of the melanoma-associated H-2D
b
–restricted epitope 
gp100 to a proline enhanced signiﬁcant peptide binding and the 
overall stability of the MHC/peptide complex compared with the 
wild-type H-2D
b
/gp100 complex (15, 18). This increased overall 
stability combined with similar conformations of the modiﬁed 
peptides compared with wild-type epitopes allowed us to enhance 
signiﬁcantly cross-reactive CD8
+ 
T cell responses toward con-
ventional cancer targets following vaccination (15). The same 
effects on increased complex stabilization were also demonstrated 
for a large ensemble of H-2D
b
– and H-2K
b
–restricted cancer-
associated peptides (15). In this study, we ﬁrst compared the af-
ﬁnity of Trh4 and Trh4p3P to H-2D
b 
using TAP-deﬁcient RMA-S 
cells as previously described (15, 34, 35) (Fig. 2A). The 
H-2D
b
/Trh4 and the proline-substituted variant displayed 
comparable binding to H-2D
b
. Because the two curves did not 
reach a plateau, we cannot  
 FIGURE 1. Immunization with Trh4-p3P efﬁciently elicited T cell proliferation and effector functions. (A) Naive wild-type C57BL/6 mice were injected 
with LnB5-tg cells and vaccinated with wild-type Trh4 or the control peptide Ad10. Blood samples were taken to follow in vivo LnB5 T cell expansion. 
The presented data are representative of at least two experiments. (B) IFN-g release by the LnB5 T cells in the presence of the wild-type or the Trh4-p3P 
peptides. T cells were mixed with splenocytes, pulsed with peptide, and IFN-g release was measured by ELISA. Data are shown as mean with SD and are 
representative of three independent experiments. (C–E) Mice were injected with LnB5-tg T cells and vaccinated with wild-type Trh4 or Trh4-p3P 
peptides. Blood was analyzed for the presence and activation status of transferred cells after the booster vaccination. Data are pooled from three 
independent experiments with two to three mice per group. (F) In vivo killing assay in which vaccinated C57BL/6 mice were injected with equal numbers 
of two differentially CFSE-labeled target cells. CFSE
low
-and CFSE
high
-labeled targets were exogenously pulsed with wild-type Trh4 and a control peptide 
(Ad10), respectively. Percentage of killing was calculated by the ratio of the two targets in spleens of mice 2 d after challenge. The data represent one 
experiment including four mice per group and are presented as mean and SEM. *p , 0.05, ***p , 0.001, by Student t test.  
calculate accurate KD values. However, the proﬁles of the two 
curves clearly indicate similar afﬁnities.  
We also performed both cell surface stability assays (Fig. 2B) and 
in vitro circular dichroism–based stabilization assays using 
soluble MHC/peptide complexes (Fig. 2C). Both assays demon-
strated that the p3P modiﬁcation of the Thr4 peptide reduced the 
overall stability of the H-2D
b
/Thr4 complex (Fig. 2B, 2C). Most 
importantly, they demonstrated that Trh4-p3P falls off the cleft of 
H-2D
b 
much faster than does wild-type Trh4. Thus, the results 
presented in Fig. 2 reveal that the binding kinetics for Trh4-p3P 
are different from wild-type Trh4, where Trh4-p3P both binds 
faster and falls out faster from H-2D
b
. Collectively, our results 
indicate that unlike our previous observations (15), although p3P 
modiﬁcation signiﬁcantly enhanced immunogenicity of the Trh4 
epitope (Fig. 1), it reduced the stability of the MHC/peptide 
complex (Fig. 2).  
The crystal structure of H-2D
b
/Trh4-p3P reveals a 
conformational modiﬁcation of the side chain of the main 
anchor residue p5M that may impact on complex stability  
To reconcile the observed very high immunogenicity of Trh4-p3P 
compared with the wild-type Trh4, with the demonstrated reduced 
overall stability of H-2D
b
/Trh4-p3P complexes, we determined 
the crystal structure of H-2D
b
/Trh4-p3P (Fig. 3). The structure 
revealed that this altered peptide ligand is presented by H-2D
b 
in a 
nearly identical way as Trh4 (12) (Fig. 4A). In H-2D
b
/Trh4-p3P, 
the p3P modiﬁcation induced a signiﬁcant conformational change 
of the side chain of the main anchor residue p5M (Fig. 4B). This 
modiﬁcation of the position of the side chain abrogates the SH–p  
and van der Waals interactions formed between Trh4 and the two 
aromatic residues W73 and Y156 in the H-2D
b
/Trh4 complex 
(Supplemental Fig. 2), and it provides the only reasonable  ex-
planation that can be derived from the comparative analysis of the 
two crystal structures that can explain the lower stability of the 
H-2D
b
/Trh4-p3P complex compared with H-2D
b
/Trh4.  
The vast majority of H-2D
b
–binding epitopes comprises an 
asparagine residue at position 5 that forms a network of hydrogen 
bonds with the H-2D
b 
residues Q97 and Q70 (Fig. 5A) (15, 18, 
22, 23, 25, 30, 36). In contrast, the nonconventional methionine 
p5M in Trh4 cannot form hydrogen bonds. The previously solved 
crystal structure of the H-2D
b
/Trh4 complex revealed that in 
addition to a large ensemble of van der Waals interactions, 
residue p5M in Trh4 formed sulfur–p interactions with H-2D
b 
residues W73 and Y156 (11) (Supplemental Fig. 2B). In H-2D
b
/ 
Trh4-p3P, the modiﬁcation of the leucine residue at position 3 to 
a proline affected profoundly the conformation of the side chain 
of p5M, which rotates and moves closer to the introduced proline 
residue toward the N-terminal part of the peptide-binding cleft 
(Fig. 4A, Supplemental Fig. 2C). Consequently, the increased 
distances between the sulfur tip of p5M and the aromatic rings of 
residues W73 and Y156 impair the formation of sulfur–p and van 
der Waals interactions betweenp5M andthese twoH-2D
b 
residues 
in H-2D
b
/Trh4-p3P. Furthermore, the side chain of p5M is 
localized closer to the polar residue Q97, which is energetically 
adverse (Supplemental Fig. 2D). Collectively, these structural 
differences provide a reasonable explanation for the observed 
lower stability of H-2D
b
/Trh4-p3P compared with H-2D
b
/Trh4.  
 FIGURE 2. Modiﬁcation of peptide position 3 signiﬁcantly reduces the overall stability of H-2D
b
/Trh4-p3P compared with H-2D
b
/Trh4. (A) The Trh4-p3P 
and the wild-type Trh4 peptides bind with equivalent efﬁciency to H-2D
b 
as measured by MHC H-2D
b 
cell surface expression on RMA-S cells. The 
H-2D
b
–binding lymphocytic choriomeningitis virus–derived peptide gp33 and the H-2D
d
–binding HIV-derived peptide P18-I10 were used as positive and 
negative controls, respectively. The presented results correspond to three independent experiments. (B) MHC/peptide stabilization assays using 
peptide-pulsed RMA-S cells (10
26 
M) reveal that cell-surface expression of H-2D
b 
in complex with Trh4-p3P is signiﬁcantly reduced compared with 
H-2D
b
/Trh4. The data are represented as mean and SD and correspond to two independent experiments. (C) Left panel, Circular dichroism denaturation 
curves of soluble H-2D
b
/Tr4-p3P (gray line) and H-2D
b
/Trh4 (black line) demonstrate a decrease of 1.65˚C in thermostability for Trh4-p3P compared with 
the wild-type Trh4 peptide. The indicated Tm values correspond to 50% denaturation for each complex. The graphs are normalized averages of four in-
dependent measurements for each MHC/peptide complex. Right panel, The Tm values are statistically signiﬁcant, with a p value of 0.0037 as determined 
using a Student t test. **p , 0.005.  
The surfaces of H-2D
b
/Trh4 and H-2D
b
/Trh4-p3P are similar, 
allowing for TCR cross-reactivity  
The conformational shift of the tip of residue p5M in Trh4-p3P 
also alters the positioning of the H-2D
b 
residues H155 and Y156, 
which both move by 0.8 A (Fig. 5C). The conformation of all 
other  
˚H-2D
b 
residues remained nearly identical between 
H-2D
b
/Trh4 and H-2D
b
/Trh4-p3P. Whereas the side chain of 
Y156 moves down toward the bottom of the peptide-binding cleft 
of H-2D
b
, the side chain of residue H155 moves up toward the 
solvent and is more readily available for interactions with TCRs 
(Supplemental Fig. 2C). However, note that the overall surfaces 
of H-2D
b
/Trh4 and H-2D
b
/Trh4-p3P remain highly similar, 
allowing for TCR cross-reactivity (Fig. 5). Ultimately, only the 
determination of the crystal structures of the TCR LnB5 in 
complex with H-2D
b
/Trh4 and H-2D
b
/Trh4-p3P will prove a 
structural basis underlying both the demonstrated cross-reactivity 
and the enhanced TCR recognition of the p3P-modiﬁed APL.  
Discussion  
Upon selection pressure of immune-mediated therapies on 
cancer lesions, immune-refractory tumor cells frequently escape 
from CD8
+ 
T cell recognition by abrogating MHC-I Ag 
presentation. In particular, deﬁciencies in processing proteins, 
including the TAP, signiﬁcantly decrease surface display of 
MHC-I/peptide  
complexes (37–39). MHC-I–presented TEIPP epitopes constitute 
a novel category of immunogenic neoantigens that are presented 
only on TAP-deﬁcient cells (4, 5, 9, 10, 12). Although derived 
from endogenous proteins, the ubiquitous TEIPP neoepitopes are 
nonmutated self-antigens that are not presented on normal cells 
(11), act as unmasked immunogenic epitopes during tumor im-
mune evasion, and are targeted by a unique category of cytotoxic 
T lymphocytes (10).  
Owing to the weak immunogenicity of the prototype TEIPP Ag 
H-2D
b
/Trh4, we investigated approaches to improve its T cell 
activating capacity. The main working template for modiﬁcations 
that may improve binding to MHC and increase TCR response 
has to our knowledge most commonly been to complement the 
interactions between main peptide anchor residues and MHC 
pockets, sometimes with great success (40, 41). Unfortunately, 
this approach did not work well for several antigenic peptides, 
most of the time due to conformational modiﬁcations and/or 
higher ﬂexibility of sections of the modiﬁed epitope. In contrast, 
we focused our attention on the possibility to modify non-
anchoring peptide residues. We have previously demonstrated for 
several tumor-associated epitopes that proline substitution of the 
nonanchor residue at position 3 substantially increased the overall 
stability of the MHC/peptide complexes without altering the 
conformation of the altered peptide ligands compared with the  
  
FIGURE 3. The overall structure of H-2D
b
/Trh4-p3P reveals a non-
canonical binding pattern, nearly identical to Trh4. (A) The 2Fo-Fc elec-
tron density map of Trh4-p3P bound to H-2D
b 
contoured at 1.0 s allows 
for unambiguous positioning of all side chains. The peptide is depicted 
with the N and C termini to the left and right, respectively. Residues p1M, 
p4R, p6T, p7A, and p8V protrude toward the TCR. Residues p2C, p3P, 
p5M, and p9M are buried within the peptide-binding cleft of H-2D
b
.  
(B) Top view of the surface of H-2D
b 
in complex with Trh4-p3P. The 
negative and positive electrostatic charges are colored in red and blue, 
respectively. The Thr4-p3P epitope is represented as sticks.  
original cancer-associated epitopes (15, 18). Other research groups 
have applied our peptide modiﬁcation in a CMV-based vaccine to 
protect mice efﬁciently against melanoma (16, 17). Although not 
always true, it is widely thought that the overall stability and 
longevity of MHC/peptide complexes is directly linked to their 
immunogenicity (19, 42, 43). Until now, our own previous studies 
on conventional overexpressed cancer-and pathogen-associated 
Ags have hitherto corroborated this view (15, 18, 23). 
Accordingly, p3P modiﬁcation of the melanomaassociated 
H-2D
b
–binding epitope gp100 resulted in signiﬁcantly increased 
stability and immunogenicity. This was also true  
for a large array of H-2D
b
– and H-2K
b
–binding cancer-associated 
peptides (15). However, to our surprise, the results presented 
within this study revealed that p3P modiﬁcation of the TEIPP 
peptide Trh4 actually decreased signiﬁcantly the overall stability 
of H-2D
b 
in complex with this APL compared with H-2D
b
/Trh4 
and affected the binding kinetics of Trh4-p3P compared with 
Trh4, with faster kon and koff values. Note that a still limited amount 
of other studies has also demonstrated that high peptide 
immunogenicity is not always coupled to higher stability of the 
MHC/peptide complexes. Instead, it has been proposed that the 
observed immunogenicity could be modulated by the intrinsic 
ﬂexibility of speciﬁc portions of the presented peptides and/or 
speciﬁc residues on the MHC H chain following “anchor-ﬁxing” 
modiﬁcations (44–47). In our opinion, the results presented in the 
present study differ from these previous studies, because 1) we do 
not observe any ﬂexibility in the main chain of the peptide upon 
comparing the crystal structures of the wild-type Trh4 with the 
proline-modiﬁed variant, and 2) our results demonstrate that the 
introduction of a proline in the targeted peptide enhances TCR 
recognition independently from the overall stability of the MHC/ 
peptide complex. In this study, we speculate that rigidiﬁcation of 
the MHC/peptide complex due to the substitution of peptide po-
sition 3 to a proline facilitates TCR docking and recognition, 
resulting in stronger CD8 T cell responses. Indeed, irrefragable 
proofs for the key role of proline residues in increasing the ther-
mostability of proteins and/or protein segments have been previ-
ously provided (48, 49). For example, rigidiﬁcation of the CDRs 
of Abs or TCRs, sometimes through mutation(s) of the loops 
residues to prolines, resulted in enhanced afﬁnity to their targets 
(50, 51). Another nonexcluding possibility is that the p3P modi-
ﬁcation of the TEIPP peptide Trh4 increases substantially its re-
sistance to proteolysis, which would result in longer survival of 
the APL following vaccination, and thus possibly enhanced pre-
sentation by APCs. Indeed, it has been previously demonstrated 
that proline motifs in peptide chains and proteins reduce prote-
olysis signiﬁcantly. Only a limited number of peptidases are 
known to be able to hydrolyze proline-adjacent bonds (52).  
We have previously demonstrated the importance of SH–p in-
teractions formed between p5M and H-2D
b 
residues for the sta-
bility of the MHC/peptide complex (12). Indeed, modiﬁcation of 
p5M to a norleucine reduced drastically the overall stability of the 
MHC/peptide complex. Furthermore, the crystal structure of 
H-2D
b 
in complex with the norleucine-substituted variant of Trh4 
revealed that the conformation of the norleucine residue was 
identical to p5M in the wild-type Trh4. Thus, SH–p interactions 
are essential for Trh4 binding to H-2D
b
, and the conformational  
 
FIGURE 4. The p3P modiﬁcation impairs the formation of sulfur–p interactions between the nonconventional main anchor p5M and H-2D
b 
residues.   
(A) The conformation of the wild-type Trh4 (5E8N, light cyan) and Trh4-p3P (wheat) peptides is nearly identical. The peptides are depicted with their N 
termini to the left and their C termini to the right, following superimposition of H-2D
b 
residues 3–173. The side chains of residues at position 1, 4, 6, and 8 
of both peptides assume similar conformations. The p3P substitution results in a signiﬁcant conformational shift of the side chain of peptide residue p5M.  
 (B) Omit maps (contoured at 1.0 s in orange and blue for Trh4-p3P and Trh4, respectively) unambiguously demonstrate a conformational shift of the side 
chain of p5M in H-2D
b
/Trh4-p3P compared with H-2D
b
/Trh4.  
 modiﬁcation revealed by the crystal structure of the H-2D
b
/Trh4-
p3P complex solved in the present study reveals a conformational 
modiﬁcation of p5M following the p3P substitution, which abro-
gates SH–p interactions, explaining the observed reduced stability 
of the MHC/peptide complex.  
In a previous study, we have demonstrated that the interactions 
formed between p3P in the modiﬁed peptide gp100 and the 
aromatic ring of H-2D
b 
residue Y159 are essential for the in-
creased stability of the MHC/peptide complex (18). Progressive 
mutation of residue Y159 to phenylalanine, leucine, and alanine 
reduced dramatically the overall stability of H-2D
b
/gp100. 
However, an important result from the same study demonstrated 
that the p3P modiﬁcation allowed for identical afﬁnity of the 
soluble TCR to H-2D
b
/gp100-p3P and H-2D
b
-Y159F/ gp100-p3P. 
Thus, the rigidiﬁcation of the peptide following the mutation of 
position 3 to a proline was enough to keep a similar recognition 
by the TCR although the Y159F-modiﬁed complex displayed 
lower overall stability (18). In the H-2D
b 
/Trh4-p3P structure, it is 
evident that this interaction still exists (Supplemental Fig. 2), 
possibly contributing to the increased immunogenicity of this 
epitope.  
In the present study, our results demonstrate that despite a 
signiﬁcant impact of the p3P modiﬁcation on the kinetic stability 
of Trh4-p3P compared with Trh4, the rigidiﬁcation imposed by 
the proline residue on the peptide enhances considerably 
functional recognition by the TCR compared with the wild-type 
epitope. Until further studies are performed, only speculations can 
be made about the structural reasons underlying the faster kinetics 
for Trh4-p3P compared with Trh4. One clear possibility for the 
faster binding rate for Thr4-p3P could be due to rigidiﬁcation of 
this APL following the introduction of a proline residue. This 
could allow for more efﬁcient and thus faster binding. The 
reasons underlying the faster koff for Trh4-p3P are due to the 
conformational modiﬁcation of residue p5M, which is 
unfavorable as already described above. Still, although displaying 
a faster binding and a faster fallout to and from H-2D
b
, this APL 
elicits signiﬁcant functional responses by T cells. A future 
structural comparison of H-2D
b
/Trh4-p3P before and after 
binding to the TCR LnB5 should provide a more deﬁnite 
understanding of this phenomenon.  
Altogether, this is to our knowledge a novel result that should be 
taken in consideration upon designing new altered versions of 
pathogen or cancer-associated epitopes or in the identiﬁcation of 
potential MHC-restricted epitopes. Although the results presented 
within this study are based on only one speciﬁc peptide and its 
recognition by one H-2D
b
/Trh4–speciﬁc TCR LnB5, they clearly 
indicate that we should not eliminate the functional testing of 
epitopes with reduced overall stabilization capacity. They also  
indicate that the stability of MHC/peptide complexes can and 
should not be exclusively used for the prediction of immuno-
genicity. Our results also suggest that higher attention should be 
given to the possibilities to rigidify peptides through, for example, 
proline substitutions to enhance T cell recognition complexes.  
The interdependency of different peptide residues, such as p3L and p5M 
in wild-type Trh4, is evident from simultaneous structural and mutations 
analyses. We have previously demonstrated that mutation of either p3L or 
p5M to an alanine abolished recognitionbyLnB5(12). InH-2D
b
/Trh4, the 
bulkier side chain of p3L and the intrinsic properties of the side chain of 
p5M, which carries a sulfur atom, results in an unconventional peptide 
binding mainly through the formation of multiple sulfur–p and van der 
Waals interactions between the side chain of p5M and the H-2D
b 
residues 
W73 and Y156 (Supplemental Fig. 2B). In H-2D
b
/Trh4-p3P, this 
complex network of interactions between p5M and the H-2D
b 
residues is 
abolished (Supplemental Fig. 2D), explaining the reduced overall 
stability of H-2D
b
/Trh4p3P compared with H-2D
b
/Trh4 (Fig. 2B, 2C). 
Instead, the conformation of the side chain of p5M is profoundly affected,  
˚˚ 
with a shift of 1.4 A for the sulfur atom and 4.2 Afor the terminal 
methyl group, altogether resulting in large movement toward p3P 
and the polar H-2D
b 
residue Gln
97
, which is energetically 
unfavorable (Fig. 4, Supplemental Fig. 2C, 2D). Still, these 
modiﬁcations do not affect the overall surface of H-2D
b
/ Trh4-p3P 
compared with H-2D
b
/Trh4, keeping molecular mimicry between 
these two complexes (Fig. 4). Thus, the possible rigidiﬁcation of 
the modiﬁed complex facilitates recognition by the 
H-2D
b
/Trh4-speciﬁc TCR LnB5, and the similarities between the 
two complexes allow for effective cross-reactivity (Supplemental 
Fig. 2).  
Finally, and in our opinion, the most important result presented 
within the present study is that vaccination with Trh4-p3P results 
in signiﬁcantly higher immunogenicity, inducing much stronger 
CD8
+ 
T cell responses toward Trh4-presenting target cells com-
pared with vaccination with the wild-type epitope Trh4 (Fig. 1). 
Collectively, our results demonstrate that TEIPP-speciﬁc CD8
+ 
T 
cells, promising candidates in the treatment of tumors that have 
escaped from conventional immunotherapies, can be successfully 
elicited to signiﬁcantly enhance recognition of cancer target cells.  
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Supplementary Figure 1  
 
 
Supplementary Figure 1. The conformational shift of p5M in H-2D
b
/Trh4-p3P abrogates sulfur-S 
interactions,explainingthe reducedstabilityoftheMHC/peptidecomplex A) The prototypic main anchor 
residue asparagine at position 5 of the H-2D
b
-restricted epitope gp33 (1S7U) 
formshydrogenbonds(greydashes)withthesidechainoftheH-2D
b 
heavychainresiduesQ70andQ97. B) The sulfur 
atomin the main anchor residue p5M in wild-type Trh4 (5E8N) formssulfur-S_yellow dashes_and 
vanderWaalsinteractionswiththeH-2D
b 
residuesW73andY156. C) Thep3Psubstitution(residue notshown)causes a 
shiftintheconformationofthesidechainofp5Maswell as theH-2D
b 
residuesY156andH155. D) The conformational 
shift of peptide residue p5M in Thr4-p3P abolishes the sulfur-S interactions formed between the sulfur tip of p5M 
and both Y156 and W73 present in H-2D
b
/Trh4, and previously demonstrated as essential for the stability of the 
MHC/peptide complex. Only the side chain of peptide residue p5 is shown for clarity.  
 
Supplementary Figure 
2  
 
Supplementary Figure 2. The side chain of p3P forms CH- 
and 
van der 
Waals 
interacti
ons with 
the 
heavy 
chain 
residue 
Y159  
The side chain of the proline residue p3P forms CH-S and van der Wa ls 
interactions with the heavy chain residue Y159 (black dashed lines). The 
hydrogen bond formed between Y159 and the main chain oxygen of p1M is 
displayed as a green dashed line. H-2D
b
/Trh4 and H-2D
b
/Trh4-p3P residues are 
displayed in light blue and wheat, respectively. Negatively and positively 
charged atoms are in red and blue, respectively.  
  Supplementary Table 
I  
Values in parentheses are for the highest resolution shell  
1
Rmerge = ∑hkl ∑i │Ii (hkl) - ‹I (hkl)›│/ ∑hkl ∑i Ii (hkl) , where Ii(hkl) is the ith observation of reflection hkl and ‹I (hkl)› is 
the weighted average intensity for all observations i of reflection hkl.  
2
Rcryst = Σ||Fo| - |Fc||/Σ|Fo|, where |Fo| and |Fc| are the observed and calculated structure factor amplitudes of 
a particular reflection and the summation is over 95 % of the reflections in the specified resolution range. The 
remaining 5 % of the reflections were randomly selected (test set) before the structure refinement and not 
included in the structure refinement.  
3
Rfree was calculated over these reflections using the same equation as for Rcryst.  
Supplementary Table I. Data collection and refinement statistics  
 
 H-2Db/Trh4-p3P  
PDB code  5MZM  
Data collection   
Spacegroup  I 1 2 1  
Cell dimensions  a, b, c (Å)  91.35, 125.01, 
98.05  
  α, β, γ (°)  90.0, 103.53, 90.0  
Resolution (Å)  58.5-2.4 
(2.49-2.40)  
No of reflections  41766 (4378)  
Rmerge 1  0.087 (0.29)  
I/σ(I)  7.0 (2.1)  
Multiplicity  3.6 (3.6)  
Completeness (%)  99.9 (100.0)  
CC (1/2)  0.991 (0.913)  
  
Refinement statistics   
Rcryst/Rfree (%)  22.63/26.81  
Mean B-factor (Å2)  48.96  
  
Deviations from ideal values   
Bond length (Å)  0.003  
Bond angles (°)  0.657  
  
Ramachandran plot   
In favoured region (%)  97.02  
Outliers (%)  0.14  
